Imipramine
Non-Selective Monoamine Reuptake Inhibitors
- Drug class
- Non-Selective Monoamine Reuptake Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 18
Overview
Imipramine is an active pharmaceutical ingredient in the Non-Selective Monoamine Reuptake Inhibitors group (N06AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 17 | May 1, 2026 |
| US United States | FDA | 1 | April 13, 2026 |
GBUnited Kingdom· MHRA
17 products
Uses
For the treatment of the symptoms of depressive illness and for the relief in children of nocturnal enuresis.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Depression -For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. Childhood Enuresis -May be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests.
In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. The effectiveness of treatment may decrease with continued drug administration.
How to take
Drug interactions
Known interactions involving Imipramine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL334140052 · revised September 20, 2024
- [2]FDA DailyMed · 02c19a0a-3d9d-48… · revised April 13, 2026 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.